Navigation Links
Lilly Announces New Vice President of Oncology Research
Date:3/10/2011

INDIANAPOLIS, March 10, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Greg Plowman, M.D., Ph.D., will lead Lilly's oncology research efforts as the vice president, oncology research and senior vice president of ImClone Systems research.

In this innovative new role created by Lilly and ImClone, Plowman will oversee the oncology research efforts of both Lilly and its subsidiary, ImClone. Plowman will be based at ImClone's research center at the Alexandria Center™ for Life Science New York City and will start on March 28, 2011.

He will report jointly to Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories (LRL), and Bernhard Ehmer, M.D., president of ImClone.

Oncology Research at Lilly, ImClone

"Oncology represents a major area of unmet medical need and rapidly advancing science is driving us to discover new treatments with better efficacy to prolong the survival of the patients we serve," said Lundberg. "The introduction of a new oncology research leader across Lilly and ImClone will ensure the pursuit of the right mechanisms, therapeutic agents and tailoring strategies across our oncology business."

"Greg's position is unique and his experience makes him an ideal choice for this new position," added Lundberg. "We believe it is one of the most exciting leadership positions in the industry given the breadth of our preclinical pipeline in both small and large molecules and the close working relationship with our clinical development group that tailors our medicines for patient needs."

Lilly acquired ImClone in 2008, broadening the Lilly Oncology portfolio and strengthening its oncology pipeline and biotech capabilities.  The company now has one of the largest clinical-stage pipelines of potential cancer medicines in the industry with more than 30 molecules.

About Greg Plowman

"Greg has a strong industry track record with experience in both biotech and big pharma," said Ehmer. "His leadership style and breadth of experience will help ensure a synergistic approach to our oncology pipeline efforts while preserving the innovative cultures of Lilly and ImClone for the benefit of the patients we serve.  This is critical for a collaboration of the size, scope and importance of the Lilly / ImClone partnership."

Prior to accepting this position, Plowman served as a senior director in research for six years at Genentech, a member of the Roche Group.  He directed research efforts in anti-angiogenesis (attempting to block the formation of blood vessels that supply nutrients and oxygen that encourage cancerous tumor growth), biomedical imaging, and tumor biology and was responsible for building a pipeline of innovative agents for treatment of cancer and ocular disease.

He has 25 years of experience in cancer research including leadership roles at four biotechs (Oncogen, Sugen, Exelixis, and Genentech) that became part of three pharmaceutical companies (Bristol-Myers Squibb, Pharmacia, and Roche).

Plowman received a bachelor's of arts in biology and chemistry from Whitman College, Walla Walla, Washington and earned his M.D. and Ph.D. from the University of Washington in Seattle.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... -- The global peripheral I.V. catheter market accounted for ... to grow at a CAGR of 6.0% during 2016-2022. ... share in the global market between the two types ... hospital segment accounted for the highest share in the ... I.V. catheter market is witnessing high growth rate, due ...
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES ... rights to develop and commercialize nuc -gemcitabine™ ... a Korean pharmaceutical company. nuc ... aptamer against surface nucleolin found on many cancer ... Unlike ADCs (antibody drug conjugates) or SMDCs (small ...
(Date:1/23/2017)... 23, 2017  Based on its recent analysis ... recognizes Ansell, a global leader in protection solutions, ... of the Year Award. Ansell,s comprehensive product portfolio, ... global footprint have placed it in a position ... The Company,s established product line and robust innovation ...
Breaking Medicine Technology:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... Sharon Kleyne, ... the air to educate listeners about the benefits of making new water infrastructure a ... Kleyne said, “it’s appropriate that we expect water infrastructure to become a top priority ...
(Date:1/23/2017)... Indiana (PRWEB) , ... January 23, 2017 , ... ... Center for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at ... 23. The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture measurement ... the right method is paramount to success. Selecting an inappropriate measurement method can ... multiple persons use the same equipment. Rare or expensive substances are wasted and ...
(Date:1/23/2017)... Viejo, California (PRWEB) , ... January 23, 2017 , ... "ProRandom is a set of ... camera to create dynamic looks in Final Cut Pro X," said Christina Austin - CEO ... of up to two layers of text with video footage. ProRandom works by using ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), the Foundation ... the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages ...
Breaking Medicine News(10 mins):